Global RNAi for Therapeutic Supply, Demand and Key Producers, 2026-2032
Description
The global RNAi for Therapeutic market size is expected to reach $ 16340 million by 2032, rising at a market growth of 26.8% CAGR during the forecast period (2026-2032).
RNA interference (RNAi) therapeutics is an advanced molecular medicine technology that utilizes double-stranded RNA molecules (such as siRNA or shRNA) to selectively silence target gene expression, thereby blocking pathogenic gene transcription or translation to achieve precise treatment of various genetic disorders, rare diseases, cancers, and viral infections. Without altering the DNA sequence, RNAi therapy offers reversible, highly specific, and low-toxicity interventions at the RNA level. Since the approval of the first RNAi drug, the field has rapidly transitioned from research to commercialization, showing immense potential in targeting the liver, nervous system, and oncology. With breakthroughs in delivery systems and expanding clinical pipelines, RNAi therapeutics is emerging as a strategic pillar in precision medicine and gene therapy industries.
The global deployment of RNAi therapeutics is accelerating, driven by multiple dimensions: breakthroughs in genomics and RNA biology have enabled higher-precision drug design; advancements in novel delivery technologies such as lipid nanoparticles (LNP) and GalNAc conjugates have significantly improved targeting efficiency to the liver and other tissues; and fast-track review policies by regulatory agencies in multiple countries have shortened the path from R&D to commercialization. Leading pharmaceutical and biotech companies are actively expanding the range of clinical indications through mergers, acquisitions, and collaborations, facilitating the market rollout of RNAi therapies in rare diseases, metabolic disorders, and cardiovascular diseases.Despite its disruptive potential, RNAi therapeutics faces technical, commercial, and regulatory hurdles. Delivery efficiency and tissue specificity remain key bottlenecks, especially in achieving effective delivery to the central nervous system and solid tumors. Additionally, RNAi molecules may trigger non-specific immune responses or off-target effects, affecting both safety and efficacy. From a business perspective, high production costs and stringent quality control standards constrain scalability and profit margins. Intellectual property barriers and the concentration of core patents among a few leading companies further raise the technical and legal thresholds for new entrants.Demand in downstream markets is becoming increasingly segmented and diversified. Rare disease treatment, lacking effective therapies, is highly reliant on RNAi solutions, making it an early commercialization breakthrough. Cardiovascular and metabolic diseases, with their vast patient populations, offer long-term growth potential. In oncology and immunotherapy, RNAi is forming novel combination approaches with checkpoint inhibitors, CAR-T, and other treatments. With the rise of personalized medicine and companion diagnostics, RNAi therapies will become more deeply integrated into precision stratification and targeted intervention clinical pathways, driving demand toward higher efficiency, safety, and controllability.
This report studies the global RNAi for Therapeutic demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for RNAi for Therapeutic, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of RNAi for Therapeutic that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global RNAi for Therapeutic total market, 2021-2032, (USD Million)
Global RNAi for Therapeutic total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: RNAi for Therapeutic total market, key domestic companies, and share, (USD Million)
Global RNAi for Therapeutic revenue by player, revenue and market share 2021-2026, (USD Million)
Global RNAi for Therapeutic total market by Type, CAGR, 2021-2032, (USD Million)
Global RNAi for Therapeutic total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global RNAi for Therapeutic market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Arrowhead, Silence Therapeutics, Benitec Biopharma, Phio Pharmaceuticals, RXi Pharmaceuticals, Arrakis Therapeutics, Benitec Biopharma, miRagen Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world RNAi for Therapeutic market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global RNAi for Therapeutic Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global RNAi for Therapeutic Market, Segmentation by Type:
siRNA
miRNA
shRNA
Global RNAi for Therapeutic Market, Segmentation by Application:
Cancer
Cardiovascular
HBV
Others
Companies Profiled:
Alnylam Pharmaceuticals
Arrowhead Pharmaceuticals
Arrowhead
Silence Therapeutics
Benitec Biopharma
Phio Pharmaceuticals
RXi Pharmaceuticals
Arrakis Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Key Questions Answered
1. How big is the global RNAi for Therapeutic market?
2. What is the demand of the global RNAi for Therapeutic market?
3. What is the year over year growth of the global RNAi for Therapeutic market?
4. What is the total value of the global RNAi for Therapeutic market?
5. Who are the Major Players in the global RNAi for Therapeutic market?
6. What are the growth factors driving the market demand?
RNA interference (RNAi) therapeutics is an advanced molecular medicine technology that utilizes double-stranded RNA molecules (such as siRNA or shRNA) to selectively silence target gene expression, thereby blocking pathogenic gene transcription or translation to achieve precise treatment of various genetic disorders, rare diseases, cancers, and viral infections. Without altering the DNA sequence, RNAi therapy offers reversible, highly specific, and low-toxicity interventions at the RNA level. Since the approval of the first RNAi drug, the field has rapidly transitioned from research to commercialization, showing immense potential in targeting the liver, nervous system, and oncology. With breakthroughs in delivery systems and expanding clinical pipelines, RNAi therapeutics is emerging as a strategic pillar in precision medicine and gene therapy industries.
The global deployment of RNAi therapeutics is accelerating, driven by multiple dimensions: breakthroughs in genomics and RNA biology have enabled higher-precision drug design; advancements in novel delivery technologies such as lipid nanoparticles (LNP) and GalNAc conjugates have significantly improved targeting efficiency to the liver and other tissues; and fast-track review policies by regulatory agencies in multiple countries have shortened the path from R&D to commercialization. Leading pharmaceutical and biotech companies are actively expanding the range of clinical indications through mergers, acquisitions, and collaborations, facilitating the market rollout of RNAi therapies in rare diseases, metabolic disorders, and cardiovascular diseases.Despite its disruptive potential, RNAi therapeutics faces technical, commercial, and regulatory hurdles. Delivery efficiency and tissue specificity remain key bottlenecks, especially in achieving effective delivery to the central nervous system and solid tumors. Additionally, RNAi molecules may trigger non-specific immune responses or off-target effects, affecting both safety and efficacy. From a business perspective, high production costs and stringent quality control standards constrain scalability and profit margins. Intellectual property barriers and the concentration of core patents among a few leading companies further raise the technical and legal thresholds for new entrants.Demand in downstream markets is becoming increasingly segmented and diversified. Rare disease treatment, lacking effective therapies, is highly reliant on RNAi solutions, making it an early commercialization breakthrough. Cardiovascular and metabolic diseases, with their vast patient populations, offer long-term growth potential. In oncology and immunotherapy, RNAi is forming novel combination approaches with checkpoint inhibitors, CAR-T, and other treatments. With the rise of personalized medicine and companion diagnostics, RNAi therapies will become more deeply integrated into precision stratification and targeted intervention clinical pathways, driving demand toward higher efficiency, safety, and controllability.
This report studies the global RNAi for Therapeutic demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for RNAi for Therapeutic, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of RNAi for Therapeutic that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global RNAi for Therapeutic total market, 2021-2032, (USD Million)
Global RNAi for Therapeutic total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: RNAi for Therapeutic total market, key domestic companies, and share, (USD Million)
Global RNAi for Therapeutic revenue by player, revenue and market share 2021-2026, (USD Million)
Global RNAi for Therapeutic total market by Type, CAGR, 2021-2032, (USD Million)
Global RNAi for Therapeutic total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global RNAi for Therapeutic market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Arrowhead, Silence Therapeutics, Benitec Biopharma, Phio Pharmaceuticals, RXi Pharmaceuticals, Arrakis Therapeutics, Benitec Biopharma, miRagen Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world RNAi for Therapeutic market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global RNAi for Therapeutic Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global RNAi for Therapeutic Market, Segmentation by Type:
siRNA
miRNA
shRNA
Global RNAi for Therapeutic Market, Segmentation by Application:
Cancer
Cardiovascular
HBV
Others
Companies Profiled:
Alnylam Pharmaceuticals
Arrowhead Pharmaceuticals
Arrowhead
Silence Therapeutics
Benitec Biopharma
Phio Pharmaceuticals
RXi Pharmaceuticals
Arrakis Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Key Questions Answered
1. How big is the global RNAi for Therapeutic market?
2. What is the demand of the global RNAi for Therapeutic market?
3. What is the year over year growth of the global RNAi for Therapeutic market?
4. What is the total value of the global RNAi for Therapeutic market?
5. Who are the Major Players in the global RNAi for Therapeutic market?
6. What are the growth factors driving the market demand?
Table of Contents
129 Pages
- 1 Supply Summary
- 2 Demand Summary
- 3 World RNAi for Therapeutic Companies Competitive Analysis
- 4 United States VS China VS Rest of World (by Headquarter Location)
- 5 Market Analysis by Type
- 6 Market Analysis by Application
- 7 Company Profiles
- 8 Industry Chain Analysis
- 9 Research Findings and Conclusion
- 10 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
